2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

In the summer of 2018, a draft order of the Russian Government “On Approval of the
Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for
the Period up to 2030” (hereinafter referred to as the “Pharma-2030 Strategy”) was published
in the federal information system.
The Pharma-2030 strategy is focused on meeting the national goals and strategic objectives
of the Russian Federation. According to the Decree of the President No. 204 of May 7, 2018
“On national goals and strategic objectives of the development of the Russian Federation for
the period up to 2024”, the main goals and objectives in relation to the pharmaceutical
industry development are:
§ breakthrough scientific, technological and socially oriented development of the
Russian Federation and acceleration of the technological development of the Russian
Federation;
§ creation of a highly productive export-oriented sector in the basic sectors of economy,
developing on the basis of modern technologies and provided with highly qualified
personnel;
§ increasing the life expectancy of the population up to 78 years (by 2030 – up to 80
years).
According to the draft Strategy “Pharma-2030”, the main goal of the Russian state policy for
pharmaceutical industry development for the period up to 2030 is:
§ guaranteeing the security of the Russian Federation in the matter of drug supply to
the population and drug availability in all segments;
§ ensuring the advanced level of scientific, technical and technological development of
the pharmaceutical industry;
§ creation of export-oriented potential of the pharmaceutical industry;
§ availability of competencies in R&D, full-cycle production, introduction into clinical
practice and export of innovative medicines.
Expected results of the Strategy implementation are:
§ a significant increase in the volume and range of production of pharmaceutical
products to ensure the domestic market and the development of exports of finished
pharma products and pharmaceutical substances;
§ implementation of modern digital platforms in the industry and best regulatory
practices in the pharmaceutical industry;
§ meeting the needs of the healthcare system and the population in accordance with
the designated state priorities, as well as in the most expensive or voluminous niches
of the pharmaceutical market;
§ creation of a personnel training system to meet the needs of the pharmaceutical
industry, including the advanced educational and scientific infrastructure, among
other things via creating consortia with technology partners;
§ development of innovative, technical and technological infrastructure, increasing the
share of intangible assets of companies with the objective, among other things, of
increasing the export of pharmaceutical products.
RUSSIAN-FINNISH LIFE SCIENCE INDUSTRY 29
Research and export directory